AR023681A1 - Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento. - Google Patents

Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento.

Info

Publication number
AR023681A1
AR023681A1 ARP990105055A ARP990105055A AR023681A1 AR 023681 A1 AR023681 A1 AR 023681A1 AR P990105055 A ARP990105055 A AR P990105055A AR P990105055 A ARP990105055 A AR P990105055A AR 023681 A1 AR023681 A1 AR 023681A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
group
alkoxy
ring
Prior art date
Application number
ARP990105055A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9821976.9A external-priority patent/GB9821976D0/en
Priority claimed from GBGB9824340.5A external-priority patent/GB9824340D0/en
Priority claimed from GBGB9910711.2A external-priority patent/GB9910711D0/en
Priority claimed from GBGB9918032.5A external-priority patent/GB9918032D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR023681A1 publication Critical patent/AR023681A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de tetrahidrobenzazepina caracterizados porque tienen la formula 1 en la que R1 representa un sustituyente seleccionado entre: un átomo dehidrogeno o de halogeno; un grupo hidroxi, ciano, nitro, trifluorometilo, trifluorometoxi, trifluorometanosulfoniloxi, pentafluoretilo, alquilo C1-4, alcoxiC1-4, aril-alcoxi C1-4, alquil C1-4-tio, alcoxi C1-4-alquilo C1-4, cicloalquilo C3-6-alcoxi C1-4, alcanoilo C1-4, alcoxi C1-4-carbonilo, alquil (C1-4)sulfoniloalquil(C1-4)sulfonilo-alquilo C1-4, arilsulfonilo, arilsulfoniloxi, arilsulfonil-alquilo C1-4, alquil(C1-4)amido, alquil(C1-4)sulfonamido-alquilo C1-4,alquil(C1-4)amido-alquilo C1-4, arilsulfonamido, arilcarboxamido, arilsulfonamido-alquilo C1-4, arilcarboxamido-alqilo C1-4, aroilo, aroil-alquilo C1-4, oaril-alcanoilo C1-4; un grupo R3OCO(CHA2)p, R3R4NCO(CH2)p o R3R4NSO2(CH2)p, en cada una de cuyas formulas R3 y R4 , independientemente, representa un átomo dehidrogeno o un grupo alquilo C1-4 o R3R4 forma parte de un anillo de azacicloalcano C3-6 o (2-0x0)azacicloalcano C3-6 y p representa cero o un numero enterodesde 1 a 4; o un grupo Ar3Z, en el que Ar3 representa un anillo de fenilo opcionalmente sustituido o un anillo heterocíclico aromático de 5 o 6 miembrosopcionalmente sustituido, y z representa un enlace, O, S, o CH2; R2representa un átomo de hidrogeno o un grupo alquilo C1-4; q es 1 o 2; A representa un grupode la formula (a), (b) (c) o (d): en las que Ar representa un anillo de fenilo opcionalmente sustituido o un anillo heterocíclico aromático de 5 o 6 miembrosopcionalmente sustituido; o un sistema de anillos bicíclicos opcionalmente sustituído; Ar1 y Ar2, cada uno independientemente, representan un anillo de feniloopcionalmente sustituido o un anillo heterocíclico aromático de 5 o 6 miembros opcionalmente sustituído; e Y representa un enlace, -NHCO-, -CONH-, -CH2- o-(ch2)m Y1(CH2)n-, en cuyas formulas Y1 representa O, S, SO2 o CO, y m y n representan cada uno cero o 1, de tal modo que la suma de m'n es cero o 1; con talque cuando A representa un grupo de formula (a), cualquier sustituyente presente en Ar en posicion orto respecto de carboxamida es necesariamente un hidrogeno
ARP990105055A 1998-10-08 1999-10-06 Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento. AR023681A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9821976.9A GB9821976D0 (en) 1998-10-08 1998-10-08 Compounds
GBGB9824340.5A GB9824340D0 (en) 1998-11-06 1998-11-06 Compounds
GBGB9910711.2A GB9910711D0 (en) 1999-05-07 1999-05-07 Compounds
GBGB9918032.5A GB9918032D0 (en) 1999-07-30 1999-07-30 Compounds

Publications (1)

Publication Number Publication Date
AR023681A1 true AR023681A1 (es) 2002-09-04

Family

ID=27451837

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105055A AR023681A1 (es) 1998-10-08 1999-10-06 Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento.

Country Status (30)

Country Link
US (1) US6605607B1 (es)
EP (1) EP1119563B1 (es)
JP (1) JP2002527433A (es)
KR (1) KR20010085898A (es)
CN (1) CN1329609A (es)
AP (1) AP2001002114A0 (es)
AR (1) AR023681A1 (es)
AT (1) ATE316969T1 (es)
AU (1) AU761018B2 (es)
BG (1) BG105467A (es)
BR (1) BR9914370A (es)
CA (1) CA2346689A1 (es)
CO (1) CO5140073A1 (es)
CZ (1) CZ20011270A3 (es)
DE (1) DE69929704T2 (es)
EA (1) EA200100428A1 (es)
ES (1) ES2255311T3 (es)
HK (1) HK1038745A1 (es)
HU (1) HUP0104280A3 (es)
ID (1) ID28385A (es)
IL (1) IL142388A0 (es)
MA (1) MA26696A1 (es)
NO (1) NO20011745L (es)
NZ (1) NZ511018A (es)
OA (1) OA11663A (es)
PE (1) PE20001088A1 (es)
PL (1) PL347237A1 (es)
SK (1) SK4782001A3 (es)
TR (1) TR200101025T2 (es)
WO (1) WO2000021951A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
BR9914370A (pt) 1998-10-08 2001-11-27 Smithkline Beecham Plc Derivados de tetraidrobenzazepina úteis comomoduladores de receptores para a dopamina d3(agentes antipsicóticos)
EP1283199A4 (en) * 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANIN CONCENTRATION HORMONE ANTAGONIST
CZ20031311A3 (cs) * 2000-11-14 2004-04-14 Smithkline Beecham P. L. C. Deriváty tetrahydroazepinu, užitečné jako modulátory receptorů dopaminu D3 (antipsychotická činidla)
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
US20050176759A1 (en) * 2001-12-21 2005-08-11 Mahmood Ahmed 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders
JP2005517705A (ja) * 2002-02-13 2005-06-16 グラクソ グループ リミテッド ベンゼンスルホンアミド誘導体ならびにドーパミンd3およびd2受容体リガンドとしてのその使用
ATE416168T1 (de) 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
GB0224083D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
HUE055434T2 (hu) 2003-04-11 2021-11-29 Ptc Therapeutics Inc 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
US8207160B2 (en) 2003-12-18 2012-06-26 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
JP2007529514A (ja) * 2004-03-17 2007-10-25 グラクソ グループ リミテッド M3ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005094834A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
RU2008118422A (ru) * 2005-10-13 2009-11-20 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми (De) Производные 5-хинолина, обладающие антибактериальной активностью
RS56931B1 (sr) * 2013-12-13 2018-05-31 Pf Medicament Hromonski derivat kao antagonist dopaminskog d3 receptora za upotrebu u lečenju poremećaja autističnog spektra
EA032779B1 (ru) 2014-03-06 2019-07-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
WO2017075312A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
WO2018021447A1 (ja) 2016-07-28 2018-02-01 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する含窒素縮環化合物
MX2020013936A (es) 2017-03-20 2022-12-01 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato cinasa (pkr).
CN111433201B (zh) * 2017-12-21 2022-05-27 江苏恒瑞医药股份有限公司 苯并氮杂䓬衍生物、其制备方法及其在医药上的应用
BR112020014875A2 (pt) 2018-01-26 2020-12-08 Shionogi & Co., Ltd. Composto cíclico condensado tendo antagonismo de receptor de dopamina d3
CN110498768A (zh) * 2018-05-17 2019-11-26 上海中泽医药科技有限公司 庚嗪类化合物及其在制备抗精神分裂症药物中的应用
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA792785B (en) * 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4220778A (en) 1978-10-30 1980-09-02 G. D. Searle & Co. 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof
ZA816903B (en) 1980-10-17 1983-02-23 Pennwalt Corp N-(amino(or hydroxy)-1,2,3,4,-tetrahydroisoquinolines, precursors thereof, and methods of preparation
IL63918A0 (en) 1980-10-17 1981-12-31 Pennwalt Corp N-(amino(or hydroxy)phenethyl)-1,2,3,4-tetrahydroisoquinolines,their preparation and pharmaceutical compositions containing them
FR2618149B1 (fr) 1987-07-16 1989-09-22 Synthelabo Derives de n-aminoalkyl n-phenyl arylamides, leur preparation et leur application en therapeutique
IL89156A (en) 1988-07-12 1993-05-13 Synthelabo Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics
US5217977A (en) 1989-02-28 1993-06-08 Imperial Chemical Industries Plc Heterocyclic cycloalkanes
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US5681956A (en) 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5633376A (en) 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
AU652996B2 (en) 1991-01-11 1994-09-15 Laboratoires Glaxo S.A. Acridine derivatives
EP0596120A4 (en) 1991-08-09 1994-07-06 Yoshitomi Pharmaceutical Thiophene compound.
US5532240A (en) 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
KR930703327A (ko) 1991-12-26 1993-11-29 고야 다다시 축합형 티오펜 화합물 및 그의 의약용도
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
DK0649410T3 (da) 1992-07-10 1997-09-15 Glaxo Lab Sa Anilidderivater.
JPH07509705A (ja) 1992-08-06 1995-10-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ドーパミンd3レセプター拮抗薬用5−(2−オキシフェニル)−ピロール誘導体
US5294621A (en) 1992-10-07 1994-03-15 Ortho Pharmaceutical Corporation Thieno tetrahydropyridines useful as class III antiarrhythmic agents
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
GB9307400D0 (en) 1993-04-08 1993-06-02 Smithkline Beecham Plc Compounds
FR2706895A1 (en) 1993-06-22 1994-12-30 Synthelabo Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics
JP2959615B2 (ja) 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
EP0705259B1 (en) 1993-06-25 1998-02-25 Smithkline Beecham Plc Phenyrrole derivatives and their use as dopamine d3 antagonists
GB9315800D0 (en) 1993-07-30 1993-09-15 Smithkline Beecham Plc Compounds
GB9315801D0 (en) 1993-07-30 1993-09-15 Smithkline Beecham Plc Compounds
BR9407515A (pt) 1993-08-12 1997-01-07 Astra Ab Composto formulação farmaceutica uso do composto processos para o tratamento de desordens neurodegenerativas ou de enxaqueca ou para a prevenção e a reversão da tolerância aos opiatos e diazepinas ou para o tratamento do vicio das drogas e para a preparação do composto
WO1995008533A1 (fr) 1993-09-21 1995-03-30 Yamanouchi Pharmaceutical Co., Ltd. Derive de n-(3-pyrrolidinyl)benzamide
GB9320855D0 (en) 1993-10-09 1993-12-01 Smithkline Beecham Plc Compounds
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
GB9325827D0 (en) 1993-12-17 1994-02-23 Smithkline Beecham Plc Compounds
GB9402197D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9403199D0 (en) 1994-02-19 1994-04-13 Smithkline Beecham Plc Compounds
CN1147248A (zh) 1994-04-28 1997-04-09 山之内制药株式会社 N-(3-吡咯烷基)苯甲酰胺衍生物
US5414010A (en) 1994-05-10 1995-05-09 Warner-Lambert Company Dimeric benzimidazoles as central nervous system agents
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
GB9418912D0 (en) 1994-09-20 1994-11-09 Fisons Corp Pharmaceutically active compounds
NZ295546A (en) 1994-10-05 1999-01-28 Glaxo Wellcome Inc Parenteral medicament containing n-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}- 9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide, surfactant, and buffer
WO1996016040A1 (en) 1994-11-23 1996-05-30 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US5478934A (en) 1994-11-23 1995-12-26 Yuan; Jun Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands
GB9426071D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426090D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
CA2213197C (en) 1995-02-15 2001-08-07 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
WO1996030333A1 (en) 1995-03-27 1996-10-03 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic agents
GB9512129D0 (en) 1995-06-15 1995-08-16 Smithkline Beecham Plc Compounds
US5977110A (en) 1995-09-22 1999-11-02 Warner-Lambert Company Substituted cyclohexylamines as central nervous systems agents
FR2741074B1 (fr) 1995-11-09 1997-12-19 Adir Nouveaux composes tetracycliques de la 1,4-oxazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
AU1597197A (en) 1996-02-01 1997-08-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Thienoquinolines
AU1618697A (en) 1996-02-06 1997-08-28 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5710274A (en) 1996-02-28 1998-01-20 Neurogen Corporation N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands
US5763609A (en) 1996-03-21 1998-06-09 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands
US5703237A (en) 1996-04-18 1997-12-30 Neurogen Corporation N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
US6046210A (en) * 1996-05-11 2000-04-04 Smithkline Beecham P.L.C. Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
JP2000517301A (ja) * 1996-08-14 2000-12-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー テトラヒドロイソキノリン誘導体およびそれらの薬理学的使用
WO1998007421A1 (fr) 1996-08-16 1998-02-26 Ishihara Sangyo Kaisha, Ltd. Composition medicinale
BR9714364A (pt) 1996-11-27 2000-03-21 Pfizer Amidas inibidoras da secreção de apo b/mtp
FR2761985B1 (fr) 1997-04-10 1999-05-21 Adir Nouveaux composes amines du 6,7,8,9-tetrahydro-cyclopenta[a] naphtalene et du 2,3-dihydro-cyclopenta[e]indene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL132169A0 (en) 1997-04-28 2001-03-19 Univ British Columbia Method and composition for modulating amyloidosis
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
WO1998050364A1 (en) * 1997-05-03 1998-11-12 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9709303D0 (en) 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710612D0 (en) 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
GB9821977D0 (en) 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
BR9914370A (pt) 1998-10-08 2001-11-27 Smithkline Beecham Plc Derivados de tetraidrobenzazepina úteis comomoduladores de receptores para a dopamina d3(agentes antipsicóticos)
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
EA200100428A1 (ru) 2001-10-22
ES2255311T3 (es) 2006-06-16
PE20001088A1 (es) 2000-12-02
KR20010085898A (ko) 2001-09-07
TR200101025T2 (tr) 2001-09-21
JP2002527433A (ja) 2002-08-27
OA11663A (en) 2004-12-08
SK4782001A3 (en) 2001-11-06
WO2000021951A1 (en) 2000-04-20
ID28385A (id) 2001-05-17
IL142388A0 (en) 2002-03-10
AU1038100A (en) 2000-05-01
MA26696A1 (fr) 2004-12-20
EP1119563A1 (en) 2001-08-01
NZ511018A (en) 2003-09-26
HUP0104280A3 (en) 2002-07-29
AP2001002114A0 (en) 2001-06-30
BR9914370A (pt) 2001-11-27
NO20011745L (no) 2001-06-06
DE69929704T2 (de) 2006-07-20
CZ20011270A3 (cs) 2001-09-12
CN1329609A (zh) 2002-01-02
CO5140073A1 (es) 2002-03-22
CA2346689A1 (en) 2000-04-20
ATE316969T1 (de) 2006-02-15
AU761018B2 (en) 2003-05-29
NO20011745D0 (no) 2001-04-06
DE69929704D1 (de) 2006-04-13
HUP0104280A2 (hu) 2002-03-28
US6605607B1 (en) 2003-08-12
BG105467A (en) 2001-11-30
HK1038745A1 (zh) 2002-03-28
PL347237A1 (en) 2002-03-25
EP1119563B1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
AR023681A1 (es) Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento.
AR013078A1 (es) Derivados de tetrahidroisoquinoleina, una sal de los mismos, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de losmismos en la preparacion de un medicamento.
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
AR008327A1 (es) Aminoguanidinas y alcoxiguanidinas como inhibidores de proteasa, alcoxiaminas para su exclusivo uso en el procedimiento de obtencion de dichos compuestos, composicion farmaceutica, uso de dichos compuestos y composiciones para preparar medicamentos, dispositivo usado en la recolección, circulacion y almacenamiento de sangre y proceso para preparar dichos compuestos.
AR033306A1 (es) Compuestos
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
AR008291A1 (es) Derivados de tetrahidroisoquinolina, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso para la preparacionde un medicamento.
MX9307654A (es) Derivados de amina, proceso para su preparacion y composicion farmaceutica que los contiene.
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
DE69507293D1 (de) Benzamid-derivate als vasopressin-antagonisten
BR0114881A (pt) Derivados de benzoxazinona, sua preparação e uso
HUP0002311A2 (hu) Ergolinszármazékok és szomatosztatin receptorként való alkalmazásuk
TR200401716T4 (tr) Yeni üç yerdeğiştirme gruplu fenil türevleri ve analogları
AR027296A1 (es) Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
AR004970A1 (es) Sales de derivados de la quinolina, composiciones farmaceuticas que comprenden dichas sales y procedimientos para preparar dichas sales.
SE8503415L (sv) Nya isoindolinylalkylpiperaziner och farmaceutiska kompositioner innehallande desamma
ATE102199T1 (de) 4-amino-3-carboxynaphthyridin-derivate, ihre herstellung und pharmazeutische zusammensetzungen.
HUP0303513A2 (hu) Szubsztituált pirazinkinoxalin-származékok mint szerotonin receptor agonisták és antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AR017146A1 (es) Compuestos de 1-(fenil-sustituido)-5-(4-metilsulfonilfenil)pirazol; procedimiento para prepararlos, las composiciones farmaceuticas que los contienen,los agentes inhibidores de la cox-ii que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos.
AR016594A1 (es) DERIVADOS DE 3,4,5,7-TETRAHIDRO-PIRROLO[3',4':4,5]TIENO[2,3-d]PIRIMIDINA 3-SUSTITUIDOS Y SU USO PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS
DK0706517T3 (da) Pyridazinonderivater med farmaceutisk virkning
HUP0004590A2 (hu) Endotelin-antagonista imidazolszármazékokat és béta receptor blokkolókat tartalmazó kombinációs gyógyszerkészítmények
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
AR012249A1 (es) Compuestos de amonio cuaternario, procedimiento para su preparacion, composicion farmaceutica que los contiene, y su uso para la preparacion de medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal